GLP-1 receptor agonists: differentiation within the class - PubMed (original) (raw)

Comment

GLP-1 receptor agonists: differentiation within the class

Simeon I Taylor. Lancet Diabetes Endocrinol. 2018 Feb.

No abstract available

PubMed Disclaimer

Figures

Figure. Magnitude of cardioprotection is correlated with HbA1c-lowering

Hazard ratios from SUSTAIN-6, LEADER, EXSCEL, and ELIXA– are plotted on the vertical axis as a function of ‘normalized’ HbA1c-lowering plotted on the horizontal axis. To account for variation in study design among six head-to-head efficacy studies–, HbA1c-lowering data were normalized as follows:

1. Normalized HbA1c-lowering for short-acting exenatide/BYETTA was defined as 1.00%.
2. Normalized HbA1c-lowering for lixisenatide was calculated based on head-to-head comparative efficacy data obtained in the GetGoal-X study. Observed HbA1c-lowering was 0.96% for short-acting exenatide/BYETTA and 0.79% for lixisenatide, corresponding to an Efficacy Ratio of 0.82 (=0.79% / 0.96%). A normalized HbA1c-lowering for lixisenatide of **0.82%**was calculated by multiplying the Efficacy Ratio (0.82) times the normalized HbA1c-lowering for short-acting exenatide (1.00%).
3. Normalized HbA1c-lowering for long-acting exenatide/BYDUREON was calculated in a similar fashion based on comparative efficacy data in the DURATION-1 study. This yielded a value of1.27% as the normalized HbA1c-lowering for long-acting exenatide [BYETTA].
4. The DURATION-6 and SUSTAIN-3 studies reported Efficacy Ratios of 1.16 and 1.67 for liraglutide and semaglutide, respectively, relative to extended-release exenatide/BYDUREON. These calculations yield values for normalized HbA1c-lowering of 1.47% and 2.12% for liraglutide and semaglutide, respectively.
5. The AWARD-6 and HARMONY-7 studies reported Efficacy Ratios of 1.04 and 0.79 for dulaglutide and albiglutide, respectively, relative to liraglutide. These calculations yield values for normalized HbA1c-lowering of1.53% and 1.16% for dulaglutide and albiglutide, respectively.

Comment in

• GLP-1 receptor agonists and cardiovascular disease: drug-specific or class effects?
  Zweck E, Roden M. Zweck E, et al. Lancet Diabetes Endocrinol. 2019 Feb;7(2):89-90. doi: 10.1016/S2213-8587(18)30351-6. Lancet Diabetes Endocrinol. 2019. PMID: 30683221 No abstract available.

Comment on

• Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis.
  Bethel MA, Patel RA, Merrill P, Lokhnygina Y, Buse JB, Mentz RJ, Pagidipati NJ, Chan JC, Gustavson SM, Iqbal N, Maggioni AP, Öhman P, Poulter NR, Ramachandran A, Zinman B, Hernandez AF, Holman RR; EXSCEL Study Group. Bethel MA, et al. Lancet Diabetes Endocrinol. 2018 Feb;6(2):105-113. doi: 10.1016/S2213-8587(17)30412-6. Epub 2017 Dec 6. Lancet Diabetes Endocrinol. 2018. PMID: 29221659

Similar articles

• Glucagon-like peptide-1 analogues for Type 2 diabetes mellitus: current and emerging agents.
  Gallwitz B. Gallwitz B. Drugs. 2011 Sep 10;71(13):1675-88. doi: 10.2165/11592810-000000000-00000. Drugs. 2011. PMID: 21902291 Review.
• An overview of once-weekly glucagon-like peptide-1 receptor agonists--available efficacy and safety data and perspectives for the future.
  Madsbad S, Kielgast U, Asmar M, Deacon CF, Torekov SS, Holst JJ. Madsbad S, et al. Diabetes Obes Metab. 2011 May;13(5):394-407. doi: 10.1111/j.1463-1326.2011.01357.x. Epub 2011 Jan 5. Diabetes Obes Metab. 2011. PMID: 21208359 Review.
• Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis.
  Htike ZZ, Zaccardi F, Papamargaritis D, Webb DR, Khunti K, Davies MJ. Htike ZZ, et al. Diabetes Obes Metab. 2017 Apr;19(4):524-536. doi: 10.1111/dom.12849. Epub 2017 Feb 17. Diabetes Obes Metab. 2017. PMID: 27981757 Review.
• Differential effects of GLP-1 receptor agonists on components of dysglycaemia in individuals with type 2 diabetes mellitus.
  Owens DR, Monnier L, Bolli GB. Owens DR, et al. Diabetes Metab. 2013 Dec;39(6):485-96. doi: 10.1016/j.diabet.2013.09.004. Epub 2013 Oct 22. Diabetes Metab. 2013. PMID: 24156868 Review.
• GLP-1 receptor agonists and HBA1c target of <7% in type 2 diabetes: meta-analysis of randomized controlled trials.
  Esposito K, Mosca C, Brancario C, Chiodini P, Ceriello A, Giugliano D. Esposito K, et al. Curr Med Res Opin. 2011 Aug;27(8):1519-28. doi: 10.1185/03007995.2011.590127. Epub 2011 Jun 13. Curr Med Res Opin. 2011. PMID: 21663496

Cited by

• An Assessment of Semaglutide Safety Based on Real World Data: From Popularity to Spontaneous Reporting in EudraVigilance Database.
  Butuca A, Dobrea CM, Arseniu AM, Frum A, Chis AA, Rus LL, Ghibu S, Juncan AM, Muntean AC, Lazăr AE, Gligor FG, Morgovan C, Vonica-Tincu AL. Butuca A, et al. Biomedicines. 2024 May 18;12(5):1124. doi: 10.3390/biomedicines12051124. Biomedicines. 2024. PMID: 38791086 Free PMC article.
• Acute pharmacodynamic responses to exenatide: Drug-induced increases in insulin secretion and glucose effectiveness.
  Taylor SI, Montasser ME, Yuen AH, Fan H, Yazdi ZS, Whitlatch HB, Mitchell BD, Shuldiner AR, Muniyappa R, Streeten EA, Beitelshees AL. Taylor SI, et al. Diabetes Obes Metab. 2023 Sep;25(9):2586-2594. doi: 10.1111/dom.15143. Epub 2023 Jun 1. Diabetes Obes Metab. 2023. PMID: 37264484 Free PMC article.
• Acute pharmacodynamic responses to exenatide: Drug-induced increases in insulin secretion and glucose effectiveness.
  Taylor SI, Montasser ME, Yuen AH, Fan H, Yazdi ZS, Whitlatch HB, Mitchell BD, Shuldiner AR, Muniyappa R, Streeten EA, Beitelshees AL. Taylor SI, et al. medRxiv [Preprint]. 2023 May 3:2023.03.15.23287166. doi: 10.1101/2023.03.15.23287166. medRxiv. 2023. PMID: 36993363 Free PMC article. Updated. Preprint.
• Pharmacological treatment of hyperglycemia in type 2 diabetes.
  Taylor SI, Yazdi ZS, Beitelshees AL. Taylor SI, et al. J Clin Invest. 2021 Jan 19;131(2):e142243. doi: 10.1172/JCI142243. J Clin Invest. 2021. PMID: 33463546 Free PMC article. Review.
• Long-Acting Injectable GLP-1 Receptor Agonists for the Treatment of Adults with Type 2 Diabetes: Perspectives from Clinical Practice.
  Morieri ML, Avogaro A, Fadini GP. Morieri ML, et al. Diabetes Metab Syndr Obes. 2020 Nov 9;13:4221-4234. doi: 10.2147/DMSO.S216054. eCollection 2020. Diabetes Metab Syndr Obes. 2020. PMID: 33204129 Free PMC article. Review.

References

1. 1. Bethel MA, Patel RA, Merrill P, et al. Cardiovascular outcomes with GLP-1 receptor agonists: A meta-analysis. Lancet Diabetes Endocrinol. 2017 in press. - PubMed
2. 1. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016;375:311–22. - PMC - PubMed
3. 1. Marso SP, Bain SC, Consoli A, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016;375:1834–44. - PubMed
4. 1. Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. N Engl J Med. 2015;373:2247–57. - PubMed
5. 1. Holman RR, Bethel MA, Mentz RJ, et al. Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2017;377:1228–39. - PMC - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • ClinicalKey
  • Elsevier Science
  • Europe PubMed Central
  • PubMed Central

• Other Literature Sources

  • The Lens - Patent Citations Database
  • scite Smart Citations